These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. Johng D; Torga G; Ewing CM; Jin K; Norris JD; McDonnell DP; Isaacs WB Prostate; 2019 Mar; 79(4):414-424. PubMed ID: 30560549 [TBL] [Abstract][Full Text] [Related]
3. MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis. Meriç N; Albayrak E; Gülbaş Z; Kocabaş F Leuk Lymphoma; 2024 Feb; 65(2):187-198. PubMed ID: 37902585 [TBL] [Abstract][Full Text] [Related]
4. Development of Small Molecule MEIS Inhibitors that modulate HSC activity. Turan RD; Albayrak E; Uslu M; Siyah P; Alyazici LY; Kalkan BM; Aslan GS; Yucel D; Aksoz M; Tuysuz EC; Meric N; Durdagi S; Gulbas Z; Kocabas F Sci Rep; 2020 May; 10(1):7994. PubMed ID: 32409701 [TBL] [Abstract][Full Text] [Related]
5. MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans. VanOpstall C; Perike S; Brechka H; Gillard M; Lamperis S; Zhu B; Brown R; Bhanvadia R; Vander Griend DJ Elife; 2020 Jun; 9():. PubMed ID: 32553107 [TBL] [Abstract][Full Text] [Related]
6. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Bhanvadia RR; VanOpstall C; Brechka H; Barashi NS; Gillard M; McAuley EM; Vasquez JM; Paner G; Chan WC; Andrade J; De Marzo AM; Han M; Szmulewitz RZ; Vander Griend DJ Clin Cancer Res; 2018 Aug; 24(15):3668-3680. PubMed ID: 29716922 [No Abstract] [Full Text] [Related]
7. Lead Optimization and Structure-Activity Relationship Studies on Myeloid Ecotropic Viral Integration Site 1 Inhibitor. Turgutalp B; Uslu M; Helvacioglu S; Charehsaz M; Gurdal EE; Sippl W; Kocabas F; Yarim M J Med Chem; 2021 Oct; 64(19):14448-14464. PubMed ID: 34542289 [TBL] [Abstract][Full Text] [Related]
8. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819 [TBL] [Abstract][Full Text] [Related]
9. Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. Alshalalfa M; Abou-Ouf H; Davicioni E; Karnes RJ; Alhajj R; Bismar TA J Cancer Res Clin Oncol; 2021 Aug; 147(8):2223-2231. PubMed ID: 33864110 [TBL] [Abstract][Full Text] [Related]
10. MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity. Whitlock NC; Trostel SY; Wilkinson S; Terrigino NT; Hennigan ST; Lake R; Carrabba NV; Atway R; Walton ED; Gryder BE; Capaldo BJ; Ye H; Sowalsky AG Oncogene; 2020 Aug; 39(34):5663-5674. PubMed ID: 32681068 [TBL] [Abstract][Full Text] [Related]
11. Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway. Yuan L; Huang X; Zhou K; Zhu X; Huang B; Qiu S; Cao K; Xu L Prostate; 2019 Jun; 79(8):826-839. PubMed ID: 30889629 [TBL] [Abstract][Full Text] [Related]
12. MEIS1 and its potential as a cancer therapeutic target (Review). Yao M; Gu Y; Yang Z; Zhong K; Chen Z Int J Mol Med; 2021 Sep; 48(3):. PubMed ID: 34318904 [TBL] [Abstract][Full Text] [Related]
13. ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells. Höll M; Koziel R; Schäfer G; Pircher H; Pauck A; Hermann M; Klocker H; Jansen-Dürr P; Sampson N Mol Carcinog; 2016 Jan; 55(1):27-39. PubMed ID: 25559363 [TBL] [Abstract][Full Text] [Related]
14. Effect of myeloid ecotropic viral integration site (MEIS) family genes on tumor microenvironment remodeling and its potential therapeutic effect. Meng L; Tian Z; Wang J; Liu X; Zhang W; Hu M; Wang M; Zhang Y Transl Androl Urol; 2021 Feb; 10(2):594-608. PubMed ID: 33718062 [TBL] [Abstract][Full Text] [Related]
15. Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells. Wright C; Iyer AKV; Kaushik V; Azad N J Cell Biochem; 2017 Nov; 118(11):3834-3845. PubMed ID: 28387458 [TBL] [Abstract][Full Text] [Related]
16. MEIS C termini harbor transcriptional activation domains that respond to cell signaling. Huang H; Rastegar M; Bodner C; Goh SL; Rambaldi I; Featherstone M J Biol Chem; 2005 Mar; 280(11):10119-27. PubMed ID: 15654074 [TBL] [Abstract][Full Text] [Related]
17. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies. Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684 [TBL] [Abstract][Full Text] [Related]
18. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression. Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385 [TBL] [Abstract][Full Text] [Related]
19. MEIS1 functions as a potential AR negative regulator. Cui L; Li M; Feng F; Yang Y; Hang X; Cui J; Gao J Exp Cell Res; 2014 Oct; 328(1):58-68. PubMed ID: 25158280 [TBL] [Abstract][Full Text] [Related]
20. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]